ViaCyte

United States · 49 Employees
About ViaCyte ViaCyte is a privately held regenerative medicine company developing novel cell replacement therapies as potential long-term diabetes treatments to achieve glucose control targets and reduce the risk of hypoglycemia and diabetes-related complications. ViaCyte's product candidates are based on directed differentiation of pluripotent stem cells into PEC-01 pancreatic islet progenitor cells, which are then implanted in durable and retrievable cell delivery devices. ViaCyte demonstrated that when effectively engrafted, PEC-01 cells can mature into glucose-responsive insulin producing cells in patients with type 1 diabetes. To accelerate and expand its efforts, ViaCyte has established collaborative partnerships with leading companies including CRISPR Therapeutics and W.L. Gore & Associates. About ViaCyte's Pipeline The PEC-Direct product candidate, currently being evaluated in the clinic, delivers ViaCyte's PEC-01 cells (pancreatic islet progenitor cells) in a non-immunoprotective device and is being developed for type 1 diabetes patients who have hypoglycemia unawareness, extreme glycemic lability, and/or recurrent severe hypoglycemic episodes. The PEC-Encap (also known as VC-01) product candidate, also undergoing clinical evaluation, delivers the same pancreatic islet progenitor cells but in an immunoprotective device. PEC-Encap is being developed for all patients with type 1 diabetes. In collaboration with CRISPR Therapeutics, ViaCyte is developing immune-evasive stem cell lines from its proprietary CyT49 cell line. These immune-evasive stem cell lines, which are being used in the PEC-QT program, have the potential to further broaden the availability of cell therapy for all patients with insulin-requiring diabetes, type 1 and type 2. In addition, a pluripotent, immune evasive cell line has the potential to be used to produce any cell in the body, thus enabling many other potential indications.

概述

国家 United States
成立时间
总部 3550 general atomics court, san diego, california, united states
电话号码 +1 858-455-3708
网站 http://www.viacyte.com
LinkedIn http://www.linkedin.com/company/viacyte-formerly-novocell-
Twitter https://twitter.com/VertexPharma
Facebook
员工数 49
行业 research,
简介 Vertex Pharmaceuticals invests in scientific innovation to create transformative medicines for people with serious diseases.

技术

ADP

Recruitment

Akamai RUM

Web Performance Monitoring

Amazon AWS

Hosting

Amazon SES

Email Delivery

Apache

Load Balancers

Atlassian Cloud

CMS

Bootstrap Framework

CSS and JavaScript Libraries

CSC Corporate Domains

Domain Name Services

DoubleClick

Ad Servers

DoubleClick Conversion

Advertising Networks

Drupal

CMS

Facebook Custom Audiences

Retargeting

Facebook Login (Connect)

Social Login

Facebook Widget

Widgets

Google Analytics

Analytics and Tracking

Google Dynamic Remarketing

Retargeting

Google Font API

Fonts

Google Maps

Other

Google Maps (Non Paid Users)

Other

Google Tag Manager

Tag Management

Greenhouse.io

Recruitment

Incapsula

Web Accelerators

JQuery 2.1.1

CSS and JavaScript Libraries

Linkedin Marketing Solutions

Advertising Networks

Microsoft Office 365

Other

Mobile Friendly

Other

New Relic

Web Performance Monitoring

Nginx

Load Balancers

OneTrust

Widgets

Outlook

Email Providers

Rackspace MailGun

Email Delivery

React Redux

CSS and JavaScript Libraries

Remote

Other

Vimeo

Online Video Platforms

VueJS

CSS and JavaScript Libraries

WP Engine

CMS

WordPress.org

CMS

Workday Recruit

Recruitment

YouTube

Online Video Platforms

常见问题

ViaCyte 在哪里?

ViaCyte 的总部位于 3550 general atomics court, san diego, california, united states

ViaCyte 的电话号码是多少?

ViaCyte 的电话号码是 +1 858-455-3708

ViaCyte 的官方网站是什么?

ViaCyte 的公司官方网站是 http://www.viacyte.com

ViaCyte 是做什么的?

Vertex Pharmaceuticals invests in scientific innovation to create transformative medicines for people with serious diseases.

ViaCyte 的业务有哪些?

biotechnology,life sciences,regenerative medicine,diabetes,cell therapy

ViaCyte 的年收入是多少?

ViaCyte 的收入是 25000000美元

ViaCyte 有多少员工?

ViaCyte 有 49 名员工

ViaCyte 属于哪个行业?

ViaCyte 从事以下行业: research

ViaCyte 使用什么技术?

ViaCyte 使用的一些流行技术包括: ADP,Akamai RUM,Amazon AWS,Amazon SES,Apache,Atlassian Cloud,Bootstrap Framework,CSC Corporate Domains,DoubleClick,DoubleClick Conversion,Drupal,Facebook Custom Audiences,Facebook Login (Connect),Facebook Widget,Google Analytics,Google Dynamic Remarketing,Google Font API,Google Maps,Google Maps (Non Paid Users),Google Tag Manager,Greenhouse.io,Incapsula,JQuery 2.1.1,Linkedin Marketing Solutions,Microsoft Office 365,Mobile Friendly,New Relic,Nginx,OneTrust,Outlook,Rackspace MailGun,React Redux,Remote,Vimeo,VueJS,WP Engine,WordPress.org,Workday Recruit,YouTube

如何联系 ViaCyte?

ViaCyte 联系信息: 电话号码:+1 858-455-3708， 网站:http://www.viacyte.com， 邮箱：ema***@***.com

ViaCyte 的社交媒体链接是什么?

ViaCyte 领英：http://www.linkedin.com/company/viacyte-formerly-novocell-,fackbook：,twitte:https://twitter.com/VertexPharma

ViaCyte 是一家上市公司吗?

不是

ViaCyte 的最后一轮融资是什么时候?

ViaCyte在2020-03-20T00:00:00.000+00:00结束了最后一轮融资,金额达32.6M$。

谁投资 ViaCyte?

ViaCyte 有 7 家投资者,包括 Bain Capital Life Sciences, TPG Capital, RA Capital Management, Sanderling Ventures、Bain Capital Life Sciences, RA Capital Management, TPG Capital Management, Sanderling Ventures、W.L. Gore & Associates、California Institute for Regenerative Medicine、Asset Management Partners, W.L. Gore & Associates, Inc, JDRF、、。

管理层

Patty D

Senior Patent Paralegal

Jasmin G

Manager, Cell & Combo Product Manufacturing

Josie B

Senior Research Associate

Hannah R

Senior Process Development Engineer

Diane Callahan

Office Manager

员工

Janice P

Scientist

Deicy Reyes

recepcion

Carl H

S. RA

Alfonso R

Device Manufacturing Technician

Deanna T

QA/QC Specialist

外贸获客 查找关键决策人

10亿+海关交易数据，1.2亿企业数据，2亿+企业联系人数据，1000千万真实采购商。覆盖200+个国家及地区，95%外贸重点拓展市场，可根据行业、经营范围等多方位挖掘目标客户。
免费试用

Top-ranked on G2 Crowd

全球B2B企业库 海关贸易数据 展会采购数据

工作更少，成就更大，销售更聪明

查找更多 B2B 联系人，丰富并验证记录
Email Address

全球B2B企业库

海关贸易数据

展会采购数据

Top-ranked on G2 Crowd

OR
Sign Up with Google